Stress in schizophrenia: An integrative view

European Journal of Pharmacology

Volumn 405, Issue 1-3, 2000, Pages 375-384

  Gispen De Wied, Christine C ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Cognition; Coping; Hypothalamic pituitary adrenal system; Immune system; Schizophrenia; Stress

Indexed keywords

CLOZAPINE; CORTICOSTEROID; HYDROCORTISONE; NEUROLEPTIC AGENT;

ADAPTATION; ANXIETY; AUTONOMIC NERVOUS SYSTEM; BEHAVIOR DISORDER; BRAIN REGION; COGNITIVE DEFECT; CONFERENCE PAPER; COPING BEHAVIOR; CORTICOSTEROID RELEASE; ENVIRONMENT; FEAR; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMMUNITY; LIMBIC SYSTEM; PERCEPTION; PHYSIOLOGY; PREFRONTAL CORTEX; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOPHRENIA; SOCIAL PSYCHOLOGY; STRESS;

HUMAN; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; STRESS, PSYCHOLOGICAL;

EID: 0034730571     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(00)00567-7     Document Type: Conference Paper

References (114)

1. Situational reactivity of autonomic functions in schizophrenic patients
2. Memory impairment in schizophrenia: a meta-analysis
3. Neurophysiological assessment of sensory gating in psychiatric inpatients: comparison between schizophrenia and other diagnoses
4. Schizophrenia: a neurophysiological evaluation of abnormal information processing
5. Expressed emotions and first-admission schizophrenia; nine-month follow-up in a French cultural environment
6. An analysis of the skin conductance orienting response in samples of American, British, and German schizophrenics
7. Psychophysiological response patterns in college students with high physical anhedonia: scores appear to reflect schizotypy rather than depression
8. Common pattern of cortical pathology in childhood-onset and adult-onset schizophrenia as identified by proton magnetic resonance spectroscopic imaging
9. Cytokine production in drug-free and neuroleptic-treated schizophrenic patients
10. Crises and life changes preceding the onset or relapse of acute schizophrenia: clinical aspects
11. Sensorimotor gating and schizophrenia: human and animal model studies
12. Symptom correlates of prepulse inhibition deficits in male schizophrenic patients
13. Neurobiological effects of lumbar puncture stress in psychiatric patients and healthy volunteers
14. The effects of metabolic stress on plasma progesterone in healthy volunteers and schizophrenic patients
15. Neuropsychological and psychophysiological correlates of psychosocial functioning in schizophrenia
16. Organization for physiological homeostasis
17. Stresses and strains of homeostasis
18. Behavioral and intellectual markers for schizophrenia in apparently healthy male adolescents
19. Psychophysiological dysfunctions in the developmental course of schizophrenic disorders
20. Autonomic abnormalities in schizophrenia: state or trait indicators?
21. Attention, startle eye-blink modification, and psychosis proneness
22. Contrasting effects of glucocorticoids on the capacity of T cells to produce the growth factors interleukin-2 and interleukin-4
23. The neuropsychiatric effects of treatment with interleukin-2 and lymphokine activated killer cells
24. Effects of stress on immune cell distribution - dynamics and hormonal mechanisms
25. Effect of acute metabolic stress on pituitary-adrenal axis activation in patients with schizophrenia
26. Family management in the prevention of morbidity of schizophrenia
27. Early intervention for first episodes of schizophrenia: a preliminary exploration
28. Neuropsychological investigations of schizophrenia and manic-depressive psychoses
29. Neurophysiological evidence for a defect in inhibitory pathways in schizophrenia: comparison of medicated and drug-free patients
30. Functional imaging and cognitive abnormalities
31. If it changes it must be a process; a study of emotion and coping during three stages of a college examination
32. Interleukin-6 plasma levels in depression and schizophrenia: comparison between the acute state and after remission
33. Startle habituation and sensorimotor gating in schizophrenia and related animal models
34. Diurnal rhythm of plasma beta-endorphin, cortisol and growth hormone in schizophrenics as compared to control subjects
35. Longitudinal study of cognitive function in first episode and recent-onset schizophrenia
36. Stressful life events and schizophrenia
37. Skin conductance orienting activity in a heterogeneous sample of schizophrenics
38. Evidence of high and low arousal in schizophrenia
39. Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: effects of confounding factors and diagnosis
40. The potential role of hypocortisolism in the pathophysiology of stress-related bodily disorders
41. Stress and immunity in humans: a meta-analytic review
42. Longitudinal neuropsychological follow-up study of patients with first-episode schizophrenia
43. Impaired autonomic nervous system - habituation in those at genetic risk for schizophrenia
44. The central adaptation syndrome: psychosocial stress as a trigger for adaptive modification of brain structure and brain function
45. Blunted cortisol response to a psychosocial stressor in schizophrenia
46. Selective impairments in the stress response in schizophrenic patients
47. Unresponsiveness to psychosocial stress in Multiple Complex Developmental Disorder
48. Clozapine treatment and its effect on neuroendocrine responses induced by the sreotonin agonist m-chlorophenylpiperazine
49. Blunted ACTH response to hypoglycemic stress in depressed patients but not in patients with schizophrenia
50. Clinical and neuropsychological correlates of cerebral ventricular enlargement in schizophrenia
51. Models for the joint effects of genotype and environment of liability to psychiatric illness
52. Electrodermal responsiveness, clinical variables, and brain imaging in male chronic schizophrenics
53. Performance of schizophrenic patients on tests sensitive to left or right frontal, temporal, or parietal function in neurological patients
54. Depressed pituitary-adrenal response to surgical stress in chronic schizophrenic patients
55. Pituitary-adrenal and parasympathetic function in chronic schizophrenic patients with postoperative ileus or hypotension
56. Normalization of information processing deficits in schizophrenia with clozapine
57. Combined dexamethasone/corticotropin-releasing hormone test in patients with schizophrenia and in normal controls
58. Psychotic symptoms and cognitive deficits: what relationship?
59. Measuring coping flexibility
60. Social skill training for schizophrenic individuals as risk for relapse
61. Plasma soluble interleukin-2 and transferring receptor in schizophrenia and major depression
62. In vivo immunomodulatory effects of clozapine in schizophrenia
63. Protective and damaging effects of stress mediators
64. Disorders of attention and perception in early schizophrenia
65. Effects of psychotropic medications on hypothalamic-pituitary-adrenal regulation
66. Clinical studies on the mechanism of action of Clozapine: the dopamine-serotonin hypothesis of schizophrenia
67. Mood and cognitive disorders in cancer patients receiving cytokine therapy
68. Coping strategies among the long-term mentally ill: categorization and clinical determinants
69. Plasma levels of interleukin-6 and tumor necrosis factor alpha in schizophrenia:eefects of clozapine treatment
70. Psychoneuroimmunology and the cytokine action in the CNS: implications for psychiatric disorders
71. Elevated circulating levels of interleukin-6 in schizophrenia
72. A differential role for interleukin-6 and tumor necrosis factor-alpha in schizophrenia?
73. Psychopharmacology of affective disorders in the 21st century
74. A prospective study of daily of daily stressors and symptomatology in schizophrenic patients
75. A heuristic vulnerability/stress model of schizophrenic episodes
76. The vulnerability/stress model of schizophrenic relapse: a longitudinal study
77. Electrodermal activity and vulnerability to schizophrenia: a review
78. Orienting in schizophrenia: habituation to auditory stimuli of constant and varying intensity in patients high and low in skin conductance responsivity
79. Electrodermal nonresponding, premorbid adjustment, and symptomatology as predictors of long-term social functioning in schizophrenics
80. P50 suppression and prepulse inhibition of the startle reflex in humans: a correlational study
81. Is it possible to be schizophrenic yet neuropsychologically normal?
82. Effects of Alzheimer's disease and gender on the hypothalamic-pituitary-adrenal axis response to lumbar puncture
83. Plasma levels of cytokines and soluble cytokine receptors during treatment with haloperidol
84. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol
85. Circadian rhythm of vital signs, norepinephrine, epinephrine, thyroid hormones and cortisol in schizophrenia
86. CSF interleukin-1 and interleukin-2 in medicated schizophrenic patients and normal volunteers
87. Limbic-hypothalamic-pituitary-adrenal axis activity and ventricular-to-brain ratio studies in affective illness and schizophrenia
88. The corticotropin-releasing hormone stimulation test in chronic schizophrenia
89. Differing lymphokine profile of functional subsets of human CD4 and CD8 T cell clones
90. Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia
91. A syndrome produced by diverse nocuous agents
92. The cognitive efficacy of atypical antipsychotics in schziophrenia
93. Deficits in sensory gating in schizophrenic patients and their relatives. Evidence obtained with auditory evoked responses
94. Neuropsychological dysfunctions in siblings discordant for schizophrenia
95. On the meaning of electrodermal nonresponding in schizophrenia
96. Neuropsychological and eye-movement abnormalities in first episode and chronic schizophrenia
97. Dexamethasone suppression test in schizophrenia: relationship to symptomatology, ventricular enlargement, and outcome
98. Bodily reactions to people and events in schizophrenics
99. Interaction between genetic vulnerability and family environment: the Finish adoptive family study of schizophrenia
100. Circadian and sleep-related endocrine rhythms in schizophrenia
101. Coping style and cognitive dysfunction in schizophrenic patients
102. Coping and cognition in schizophrenia and depression
103. Schizophrenia: a neural diathesis-stress model
104. Implications of normal brain development for the pathogenesis of schizophrenia
105. Disturbed endocrine function in the psychosis. I. Disordered homeostasis of disease process?
106. Chronic schizophrenic disorder. I. Psychophysiological responses, laterality and social stress
107. Electrodermal activity as a predictor of social functioning in female schizophrenics
108. Effects of neuroleptic treatment on cortisol and 3-methoxy-4-hydroxyphenylethyl glycol levels in blood
109. Investigations of cytokine production in whole blood cultures of paranoid and residual schizophrenic patients
110. Benzodiazepines in the treatment of schizophrenia: a review and reappraisal
111. Psychophysiological approaches to psychopathology
112. Vulnerability: a new view of schizophrenia